Development of Dapagliflozin Solid Lipid Nanoparticles as a Novel Carrier for Oral Delivery: Statistical Design, Optimization, In-Vitro and In-Vivo Characterization, and Evaluation

Controlling hyperglycemia and avoiding glucose reabsorption are significant goals in type 2 diabetes treatments. Among the numerous modes of medication administration, the oral route is the most common. Introduction: Dapagliflozin is an oral hypoglycemic agent and a powerful, competitive, reversible...

Descripción completa

Detalles Bibliográficos
Autores principales: Unnisa, Aziz, Chettupalli, Ananda K., Al Hagbani, Turki, Khalid, Mohammad, Jandrajupalli, Suresh B., Chandolu, Swarnalatha, Hussain, Talib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143250/
https://www.ncbi.nlm.nih.gov/pubmed/35631394
http://dx.doi.org/10.3390/ph15050568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143250/
https://www.ncbi.nlm.nih.gov/pubmed/35631394
http://dx.doi.org/10.3390/ph15050568

Ejemplares similares